Business & Industry
Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience
Novartis has entered into a licensing agreement with SciNeuro Pharmaceuticals focused on improving drug delivery to the brain. The Novartis and SciNeuro brain shuttle deal is valued at up to $1.7 billion and centers on an antibody-based program designed...
News
Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach
In order to broaden its portfolio in imaging and cardiovascular medicine, Bayer has agreed to purchase two experimental diagnostic imaging agents from Attralus. The Bayer-Attralus diagnostic tracers deal's financial details were not made public.
Two imaging tracers, AT-01 and AT-05,...
Business & Industry
UK Clinical Trial Regulatory Reforms Aim to Boost Research
A number of regulatory changes have been released by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to facilitate clinical research in the country. In order to expedite study approvals while maintaining patient safety, the UK clinical trial...
News
The Future of Vertigo Diagnostic and Treatment Options in 2026
Vertigo is an uncomfortable sensation in which you feel as though your body or the world is moving or spinning, even when you are stationary. Typically, vertigo is caused by problems affecting the inner ear, brain, or spinal cord....
News
Why Medical Conferences Matter in Modern Healthcare
The physical gathering of healthcare professionals, researchers, and industry leaders remains an indispensable cornerstone of progress. Far from being obsolete, medical conferences serve as the high-pressure crucibles where raw data is transformed into clinical wisdom and where the collective...
Business & Industry
Teva, Royalty Pharma $500M Deal to Advance Autoimmune Drug
Teva Pharmaceutical Industries and Royalty Pharma have signed a funding agreement valued at up to $500 million to advance the development of TEV-408, an investigational therapy for autoimmune disorders, including vitiligo. The Teva, Royalty Pharma $500M deal would be...
Drug Research
Pierre Fabre, Iktos Launch AI-Driven Oncology Drug Discovery
An integrated partnership has been formed between Pierre Fabre Laboratories and Iktos to advance AI-driven oncology drug discovery. The collaboration focuses on identifying and developing new small-molecule drug candidates by combining Iktos’ AI and robotics technologies with Pierre Fabre’s...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read